Top Stocks To Buy Right Now

To say that Apple Inc. (NASDAQ: AAPL) has a stranglehold on the tablet market is probably no more than to state the obvious. Of all devices running Apple’s iOS operating system, 28% are iPads. By contrast, just 12% of all Android devices using the operating system from Google Inc. (NASDAQ: GOOG) are tablets.

Tablets take an even smaller share of mobile devices made by Samsung Electronics. Just 9% of all Samsung Android devices are tablets while 91% are smartphones.

Now smartphones still dominate in global markets and Android-based smartphones made by Samsung own a 59% share of the market according to research firm Flurry. Samsung tablets hold a 42% share of global tablet in Flurry’s sample of more than 45,000 Android devices.

Flurry notes that the behavior of owners of Samsung’s smartphones and tablets more closely mirrors that of Apple device owners than it does that of other Android device users. Why then hasn’t Samsung penetrated the tablet market to a greater degree?

Top Stocks To Buy Right Now: Tempur-pedic International Inc (TPX)

Tempur-Pedic International Inc. manufactures, markets, and distributes bedding products in North America and internationally. Its products include pillows, mattresses, and adjustable beds, as well as various cushions and other comfort products. The company sells its mattresses and pillows under the TEMPUR and Tempur-Pedic brand names through furniture and bedding, specialty, and department stores; direct response, Internet, and own stores; chiropractors, medical retailers, hospitals, and other healthcare markets; and third party distributors. Tempur-Pedic International Inc. was founded in 1989 and is based in Lexington, Kentucky.

Advisors’ Opinion:

  • [By Masaaki Iwamoto]

    Japanese shares rose, with the Topix index (TPX) capping its second weekly advance, as financial shares and exporters climbed.

    Consumer lenders and brokerages advanced the most among the 33 Topix subsectors, gaining at least 1.3 percent. Electronics makers provided the biggest boost to the gauge. Sharp Corp. surged 8.4 percent on a report it will increase production of liquid-crystal display panels for smartphones. SoftBank (9984) Corp. closed at its highest in more than 13 years after activist investor Daniel Loeb’s hedge fund disclosed a $1 billion stake in the mobile carrier.

  • [By Yoshiaki Nohara]

    The MSCI Asia Pacific Index dropped 0.7 percent to 141.25 as of 4:16 p.m. in Hong Kong, with nine of the gauge’s 10 industry groups falling. The MSCI Asia Pacific excluding Japan Index declined 1.3 percent, with Japan’s Topix (TPX) index gaining 1 percent.

  • [By Kana Nishizawa]

    Japan’s Topix (TPX) index declined 0.4 percent, its first drop in four days, after the yen gained 0.2 percent to 99.81 per dollar. Australia’s S&P/ASX 200 Index and New Zealand’s NZX 50 Index both lost 0.6 percent. Singapore’s Straits Times Index fell 0.4 percent.

  • [By Laura Brodbeck]

    Wednesday

    Earnings Expected From: CenturyLink, Inc. (NYSE: CTL), Tempur-pedic International Inc. (NYSE: TPX), ING Group, N.V. (NYSE: ING), Time Warner Inc. (NYSE: TWX), Duke Energy Corporation (NYSE: DUK), Humana Inc. (NYSE: HUM) Economic Releases Expected: Australian unemployment rate, US CB Leading Index, eurozone retail sales, British Industrial and manufacturing production, eurozone services PMI

    Thursday

Top Stocks To Buy Right Now: Sucampo Pharmaceuticals Inc (SCMP)

Sucampo Pharmaceuticals, Inc., incorporated on December 9, 2008, is a global biopharmaceutical company focused on research, discovery, development and commercialization of drugs based on ion channel activators known as prostones. The Company’s prostone-based compounds target the ClC-2 and big potassium (BK), ion channels. It is focused on developing prostones to treat gastrointestinal, ophthalmic, neurologic, and oncology-based inflammatory disorders, and is also considering other therapeutic applications of its drug technology. The Company’s products include AMITIZA (lubiprostone) and RESCULA (unoprostone isopropyl).

AMITIZA

The Company’s AMITIZA is being marketed in the United States for three gastrointestinal indications under a license agreement, or the Takeda Agreement, with Takeda Pharmaceutical Company Limited, or Takeda. The three gastrointestinal indications include chronic idiopathic constipation (CIC), in adults, irritable bowel syndrome with constipation (IBS-C), in adult women, and opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain. AMITIZA for OIC received approval from the United States Food and Drug Administration (FDA), in April 2013. In Japan, AMITIZA is marketed under a license, commercialization and supply agreement, or the Abbott Agreement, with Abbott Japan Co. Ltd. (Abbott), for the gastrointestinal indication of chronic constipation (CC), excluding constipation caused by organic diseases. In Switzerland, the Company is marketing AMITIZA.

RESCULA

The Company holds license agreements for RESCULA in the United States and Canada and the rest of the world, with the exception of Japan, Korea, Taiwan and the People’s Republic of China. The Company is commercializing RESCULA (unoprostone isopropyl ophthalmic solution) 0.15% for the lowering of intraocular pressure (IOP), in patients with open-angle glaucoma or ocular hypertension in th e United States. RESCULA may be used as an agent or concomit! antly with other topical ophthalmic drug products to lower intraocular pressure. RESCULA is a BK channel activator and has a different mechanism of action than other IOP lowering agents on the market.

Advisors’ Opinion:

  • [By James Brumley]

    Still, for the nimble who know when to get out, OREX is one of the few cheap stocks worth a closer look.

    Sucampo Pharmaceuticals (SCMP)

    Finally, though the price of $7.60 clearly qualifies it as one pf the cheapest of the cheap stocks out there in the pharmaceutical world, that’s not the reason Sucampo Pharmaceuticals (SCMP) may be worth a look here. It’s the 30% slide we’ve seen SCMP stock suffer since peaking in mid-January. It’s not a pullback that’s bound to go unchallenged by the bulls.

  • [By Roberto Pedone]

    Another under-$10 stock that’s starting to trend within range of triggering a major breakout trade is Sucampo Pharmaceuticals (SCMP), which is engaged in the discovery, development and commercialization of proprietary drugs based on prostones, and other novel drug technologies. This stock is off to a decent start in 2013, with shares up by 26%.

    If you take a look at the chart for Sucampo Pharmaceuticals, you’ll notice that this stock has been downtrending badly for the last four months, with shares dumping hard from its high of $10.48 to its recent low of $5.40 a share. During that downtrend, shares of SCMP have been consistently making lower highs and lower lows, which is bearish technical price action. That said, the downside volatility for SCMP looks to be over in the short-term since the stock has started to reverse its downtrend and enter an uptrend. That reverse is quickly pushing shares of SCMP within range of triggering a major breakout trade above a key downtrend line.

    Traders should now look for long-biased trades in SCMP if it manages to break out above some near-term overhead resistance levels at $6.33 to $6.66 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 115,383 shares. If that breakout triggers soon, then SCMP will set up to re-test or possibly take out its next major overhead resistance levels at $7.09 to $7.67 a share. Any high-volume move above those levels will then give SCMP a chance to tag $8 to $9 a share.

    Traders can look to buy SCMP off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $5.58 to $5.40 a share. One can also buy SCMP off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Top Stocks To Buy Right Now: RAIT Financial Trust(RAS)

RAIT Financial Trust operates as a self-managed and self-advised real estate investment trust (REIT). The company, through its subsidiaries, invests in, manages, and services real estate-related assets with a focus on commercial real estate. It also offers a set of debt financing options to the commercial real estate industry along with fixed income trading and advisory services. In addition, RAIT Financial Trust owns and manages a portfolio of commercial real estate properties, and manages real estate-related assets for third parties. The company qualifies as a REIT for federal income tax purposes. As a REIT, it would not be subject to federal income tax to the extent that it distributes at least 90% of its taxable income to its shareholders. RAIT Investment Trust was founded in 1997 and is based in Philadelphia, Pennsylvania.

Advisors’ Opinion:

  • [By Marc Bastow]

    Commercial real-estate loan originator and real estate investment trust RAIT Financial Trust (RAS) raised its quarterly dividend 6% to 17 cents per share, payable April 30 to shareholders of record as of April 4. At more than an 8% yield, RAS stock has the highest yield on this week’s list of dividend stocks.
    RAS Dividend Yield: 8.14%.

  • [By Marc Bastow]

    Commercial real estate holding real estate investment trust (REIT) RAIT Financial (RAS) raised its quarterly dividend 7% to 16 cents per share, payable on Jan. 31 to share holders of record as of Jan. 7.
    RAS Dividend Yield: 7.48%

  • [By Eric Volkman]

    RAIT Financial Trust (NYSE: RAS  ) investors will be getting slightly more than they did last quarter, as a reward for putting their faith in the company (NYSE: RAS  ) . The real estate investment trust has declared a common stock dividend of $0.13 per share, to be handed out on July 31 to shareholders of record as of July 12. That amount is $0.01, or 8%, higher than RAIT’s previous distribution of $0.12, which was paid in April. Prior to that, the firm dispensed $0.10 per share.

Top Stocks To Buy Right Now: Universal Health Services Inc. (UHS)

Universal Health Services, Inc., through its subsidiaries, owns and operates acute care hospitals, behavioral health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. The company’s hospitals offer various services comprising general and specialty surgery, internal medicine, obstetrics, emergency room care, radiology, oncology, diagnostic care, coronary care, pediatric services, pharmacy services, and/or behavioral health services. As of February 24, 2012, it owned and/or operated 25 acute care hospitals and 198 behavioral health centers located in 36 states, Puerto Rico, and the U.S. Virgin Islands, as well as Washington, D.C. The company also operates six surgical hospitals, and surgery and radiation oncology centers located in four states and Puerto Rico. Universal Health Services, Inc. was founded in 1978 and is headquartered in King of Prussia, Pennsylvania.

Advisors’ Opinion:

  • [By Ben Levisohn]

    Tenets plunge has helped drag other healthcare stocks lower. Community Health (CYH) has dropped 3.6% to $42.21, HCA Holdings (HCA) has fallen 2.1% to $46.72 and Universal Health Services (UHS) is off 1% at $80.59.

  • [By John Moore]

    Universal Health Services (NYSE: UHS  ) has aggressively attacked a grown concern in America: diabetes. The company is currently developing specialty services to treat type 1 diabetes and mental health. Universal Health Services provides expert home, hospice and personal assistance care. They specialize in providing nurses who are skilled in diabetes and disease management. 

  • [By Asit Sharma]

    Universal Health Services (NYSE: UHS  )
    King of Prussia, Pa.-based Universal Health Services operates acute-care hospitals and behavioral health centers in the United States and the U.S. Virgin Islands.The company books more than $7 billion in annual revenue, and has grown its quarterly earnings more than 220% over the last five years. 

  • [By Rich Duprey]

    Hospital chain operator Universal Health Services  (NYSE: UHS  ) announced today its third-quarter dividend of $0.05 per share, the same rate it’s paid since 2010.

Top Stocks To Buy Right Now: MineralRite Corp (RITE)

MineralRite Corporation, formerly Royal Quantum Group Inc., incorporated on October 22, 1996, is a development-stage company. The Company is engaged in the acquisition, exploration and development of oil and gas and mineral properties. During the year ended December 31, 2009, the Company acquired a 36% interest in the drilling and development of the Gleason 4-16 well located in Oklahoma. In April 2013, it acquired the entire share capital of Goldfield International Inc.

The Company owns 100% interest in 1,540 acres that consist of 77 claims of prospective uranium property. The prospective uranium property is located adjacent to the Sheep Mountain Mine in Fremont County, Central Wyoming, approximately 90 miles southwest of Casper, Wyoming.

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap stocks MineralRite Corp (OTCMKTS: RITE), New China Global Inc (OTCMKTS: NCGI) and Metrospaces Inc (OTCMKTS: MSPC) have all been getting some extra attention lately in various investment newsletters thanks to a few paid promotions. Of course, there is nothing wrong with properly disclosed promotions or investor relations type of activities, but they can and often do backfire on unwary investors and traders alike. So how hot are these three small caps for investors? Here is a quick reality check:

Top Stocks To Buy Right Now: Medical Marijuana Inc (MJNA)

Medical Marijuana Inc. (MJNA), incorporated on May 23, 2005, is the publicly held company vested in the medical marijuana and industrial hemp markets. The Company is comprised of a diversified portfolio of products, services, technology and businesses solely focused on the cannabis and hemp industries. These products range from patented based cannabinoid products, to whole plant or isolated high value extracts specifically manufactured and formulated for the pharmaceutical, nutraceutical and cosmeceutical industries. In March 2013, it sold certain equipment and inventory, web domain names, phone numbers, and all existing and pending agreements with hemp production and processing facilities to CannaVEST Corp.

The Company’s services are varied, ranging from medical clinic management to the capitalization and development of existing industry business and product leaders. Services include development of cannabinoid based health and wellness products, and the de velopment of medical grade compounds. MJNA provides over 50 and patented cannabinoid delivery methods that are more socially and medically acceptable than smoking.

Advisors’ Opinion:

  • [By Dan Burrows]

    But it doesn’t end there. Investors should run away from all OTC marijuana stocks, including Medical Marijuana (MJNA), Cannabis Science (CBIS), CannaVest (CANV), MediSwipe (MWIP) and GreenGro Technologies (GRNH). As the SEC warns:

  • [By John Udovich]

    The SEC has halted trading of small cap marijuana stock Growlife Inc (OTCMKTS: PHOT) after a relatively brief trading halt for Advanced Cannabis Solutions, Inc (OTCMKTS: CANN), but Tranzbyte Corp (OTCMKTS: ERBB), Cannabis Science Inc (OTCMKTS: CBIS) and Medical Marijuana Inc (OTCMKTS: MJNA) are still very much alive. However and as I have noted (repeatedly) in the past (see here), Medical Marijuana Inc has a former CEO who has been indicted for a multi-state mortgage fraud scam/ponzi scheme while Medbox Inc (OTCMKTS: MDBX) is another marijuana stock with some “issues” that were summed up nicely in a Southern Investigative Reporting Foundation article cleverly entitled: Tinkerer, Lawyer, Hustler, Lies: One Man’s Path to a Dope Fortune. Obviously, investing in marijuana stocks is not for conservative. Nevertheless, there is still plenty of good or bad news for investors in the marijuana sector to inhale, including the following:

  • [By Bryan Murphy]

    Companies like Medical Marijuana Inc. (OTCMKTS:MJNA), Tranzbyte Corp. (OTCMKTS:ERBB), and Growlife Inc. (OTCBB:PHOT) were on the receiving end of another dose of good news on Thursday…. not that they necessarily needed it. That’s when a study conducted by researchers at the University of Texas was published, illustrating how not only did the advent of medical marijuana not increase crime, but rather, coincided with a (relative) decline in crime.

Top Stocks To Buy Right Now: Actavis Inc (ACT)

Actavis, Inc., formerly Watson Pharmaceuticals, Inc., incorporated on February 1, 1985, is a integrated global specialty pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, branded generic, brand, biosimilar and over-the-counter (OTC) pharmaceutical products. The Company also develops and out-licenses generic pharmaceutical products primarily in Europe through its Medis third-party business. The Company operates in three segments: Actavis Pharma, Actavis Specialty Brands and Anda Distribution. On January 23, 2013, the Company completed the acquisition of Uteron Pharma SA. On October 29, 2012, the Company sold its Rugby OTC pharmaceutical products and trademarks to The Harvard Drug Group, L.L.C. On January 24, 2012, the Company completed the acquisition of Ascent Pharmahealth Ltd.

Actavis Pharma Segment

Actavis Pharma Segment is engaged in the development, manufacturing and sale of generic, branded generic and OTC pharmaceutical products. The Company’s portfolio of generic products includes products it has developed internally and products licensed from and distributed for third parties. The Company sells its generic prescription products primarily under the Watson Laboratories, Watson Pharma and Actavis Pharma labels, and its over-the-counter generic products under private label.

Actavis Specialty Brands Segment

The Company markets a number of branded products to physicians, hospitals, and other markets that it serves. The Company classifies these trademarked products as its brand pharmaceutical products. In April 2012, it launched Gelnique 3% (oxybutynin), a clear, odorless topical gel. Gelnique 3% was obtained through an exclusive licensing agreement with Antares. The Company’s promoted products are Rapaflo, Gelnique, Trelstar, Androderm, Generess Fe and Crinone. The Company’s Actavis Specialty Brands segment also receives ot her revenues consisting of co-promotion revenue and royaltie! s.

Anda Distribution Segment

The Company Anda Distribution business primarily distributes generic and selected brand pharmaceutical products, vaccines, injectables and over-the-counter medicines to independent pharmacies, alternate care providers (hospitals, nursing homes and mail order pharmacies), pharmacy chains and physicians’ offices. In addition, it sells to members of buying groups, which are independent pharmacies that join together to enhance their buying power. As of December 31, 2012, the Company distributes products from its facilities in Weston, Florida, Groveport, Ohio, and Olive Branch, Mississippi, as well as a small volume of product from Puerto Rico.

The Company competes with Teva Pharmaceutical Industries, Ltd., Mylan Inc., Sandoz, Inc, McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc.,

Advisors’ Opinion:

  • [By Holly LaFon]

    The Fund’s average overweight position (20% versus 13%) and holdings in the Health Care sector (up 8% compared to up 6% for the S&P 500 sector) contributed to results. Forest Laboratories (FRX) (up 54%) agreed to be acquired by Actavis PLC (ACT). Merck (up 14%) also performed well.

  • [By Dan Burrows]

    True, that’s peanuts compared to the $100 billion Pfizer (PFE) is offering for AstraZeneca (AZN),  and just a fraction of the $46 billion Valeant (VRX) offered for Allergan (AGN). Holders of Merck stock probably know the deal between MRK and Bayer even pales compared to the $25 billion acquisition of Forest Labs (FRX) by Actavis (ACT).

  • [By Lauren Pollock]

    Actavis(ACT) PLC confirmed plans to acquire rival drug maker Forest Labs in a cash-and-stock deal that values Forest at about $25 billion. Shares of Forest Labs rose 30% to $93.06 premarket. Actavis shares rose 8.2% to $207.70.

  • [By Jake L’Ecuyer]

    Equities Trading UP
    Forest Laboratories (NYSE: FRX) shot up 29.85 percent to $92.70 after Actavis (NYSE: ACT) announced its plans to buy Forest Labs for $25 billion. Analysts at Morgan Stanley upgraded Forest Labs from Equal-Weight to Overweight.

Top Stocks To Buy Right Now: Octagon 88 Resources Inc (OCTX)

Octagon 88 Resources, Inc., incorporated on June 9, 2008, is a development-stage oil and gas company. The Company has acquired light and conventional heavy oil assets in Northern Alberta. On Jan 22, 2013, the Company launched the Conventional Oil Production Division by entering into a purchase agreement to acquire its share in the Red Earth Area, which consists of four contiguous sections of P&NG leases, a ( 40 API) Keg River formation with P3 reserves of 1.2 Mill barrels light sweet crude oil recoverable.

On December 24, 2012, the Company acquired a 22% interest of CEC North Star Energy Ltd. (North Star). On January 23, 2013, the Company acquired a 10% interest in North Star.

Advisors’ Opinion:

  • [By Jonathan Yates]

    For investors looking for a play, small cap firms operating in the oil and natural gas sector in Canada, such as Octagon 88 (OTC: OCTX), Americas Petrogas (OTC: APEOF), and Connacher Oil and Gas (OTC: CLLZF) could draw attention.

  • [By Jonathan Yates]

    It will also be bullish for publicly traded companies in each sector, ranging from prominent blue chips like Exxon Mobil (NYSE: XOM) and Goldcorp (NYSE: GG) to promising small caps like Octagon 88 (OTC: OCTX) and Wishbone Gold PLC (OTC: WISHY).

  • [By Jonathan Yates]

    There has been a great deal of concern about the United States suffering from a “lost generation” as Japan has now for several. For investors in oil, this has certainly not been the case: A recent article in The Wall Street Journal noted that oil has risen 310% (Brent Crude) over the last decade. The future looks equally promising for investments in the sector such as ConocoPhillips (NYSE: COP), Suncor Energy (NYSE: SU), Americas Petrogas (BOE.V), and Octagon 88 (OTCBB: OCTX).

  • [By Jonathan Yates]

    “Octagon 88 has received confirmation of 1.6 billion billion barrels PIIP,” was the headline for the press release dated September 11, 2013. Needless to say, Octagon 88 (OTCBB: OCTX), a small cap oil and natural gas exploration based in Switzerland with assets in the oil-rich Alberta province of Canada, has soared on that and other bullish news. From early July, the stock price for Octagon 88 just about doubled.